CytoDyn to Present at Wall Street Reporter’s “
Post# of 148187
(Total Views: 377)
Posted On: 02/10/2020 6:14:32 AM
CytoDyn to Present at Wall Street Reporter’s “NEXT SUPER STOCK Live” Conference on February 11, 2020
GlobeNewswire GlobeNewswire•February 10, 2020
VANCOUVER, Washington, Feb. 10, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., president and chief executive officer, will present a comprehensive overview of upcoming milestones anticipated in 2020 for multiple potential therapeutic indications for leronlimab at Wall Street Reporter’s “NEXT SUPER STOCK Live” Conference on Tuesday, February 11, 2020 at 12:30 p.m. ET / 9:30 a.m. PT.
Date: Tuesday, February 11, 2020
Time: 12:30 p.m. ET / 9:30 a.m. PT
Access: https://www.wallstreetreporter.com/next-super...onference/
GlobeNewswire GlobeNewswire•February 10, 2020
VANCOUVER, Washington, Feb. 10, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY), (“CytoDyn” or the “Company"
, a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., president and chief executive officer, will present a comprehensive overview of upcoming milestones anticipated in 2020 for multiple potential therapeutic indications for leronlimab at Wall Street Reporter’s “NEXT SUPER STOCK Live” Conference on Tuesday, February 11, 2020 at 12:30 p.m. ET / 9:30 a.m. PT. Date: Tuesday, February 11, 2020
Time: 12:30 p.m. ET / 9:30 a.m. PT
Access: https://www.wallstreetreporter.com/next-super...onference/
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼